A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema - DX221

Oculis Operations S.a.r.l.0 个研究点目标入组 348 人开始时间: 2024年1月31日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 348

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Signed informed consent form before any study-specific procedures are performed., Male or female adult subject aged 18 to 85 years., DME with presence of intraretinal and/or subretinal fluid in the study eye, with CST of =310 µm by SD-OCT at screening (Visit 1) (to be confirmed by CRC); CST is not part of the eligibility reconfirmation on Day 1 (Visit 2)., BCVA ETDRS letters score >35 letters (>20/200 Snellen equivalent) in the non-study eye at screening (ie, as per definition of monocular blindness)., BCVA ETDRS letters score =65 (Snellen 20/50) and =24 (Snellen 20/320) in the study eye at screening and baseline (Visit 1 and Visit 2)., Documented diagnosis of Type 1 or Type 2 diabetes mellitus and an HbA1c of = 10.0% prior to screening (Visit 1) (historic values of HbA1c taken up to 2 months before the screening visit will be permissible otherwise the study site will collect a sample for analysis at screening [Visit 1])., Anti-vascular endothelial growth factor (VEGF) and corticosteroid IVT treatment-naïve (ie, have not received previous treatment with any anti-VEGF and corticosteroid IVT) in the study eye, OR treated with anti-VEGF agents IVT and/or corticosteroids IVT in the study eye in the past and for whom the following washout periods before Day 1 apply: a. Anti-VEGF agents IVT: 3 months b. Periocular or IVT corticosteroids: i. Triamcinolone: 4 months ii. Biodegradable slow-release steroid IVT implant (eg, Ozurdex): 6 months iii. Nonbiodegradable slow-release steroid implant (eg, Iluvien, Retisert, Yutiq): 3 years, Negative urine pregnancy test at Visit 1, if women of childbearing potential (WOCBP) those who have experienced menarche and who are not surgically sterilized ([bilateral tubal ligation, hysterectomy or bilateral oophorectomy] or postmenopausal [12 months after last menses]) and must use adequate birth control throughout the study period (refer to Appendix 2 of the protocol).

排除标准

•Macular edema considered to be because of a cause other than DME. Examples included: The macular edema is considered to be related to ocular surgery, clinical exam and/or OCT suggest that vitreoretinal interface abnormalities disease, acute macular degeneration (AMD), retinal vein occlusion (RVO), uveitis., Currently enrolled in or have participated in any other clinical study involving a study drug or device, or in any other type of medical research, within 30 days before screening and up to completion of the current study., Use of systemic corticosteroids (ie, oral, IM, IV, intranasal) within 1 month prior to Day 1 and no systemic corticosteroids anticipated throughout the study., Any prior or concomitant systemic anti-VEGF treatment within 6 months prior to Day 1., Any other medical condition that in the opinion of the investigator may affect BCVA, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject’s participation in the study., Decrease in BCVA because of causes other than DME., Known history of significant macular ischemia which would prevent gain in visual acuity in the study eye., Any other ocular disease in the study eye that may cause substantial reduction in BCVA, including retinal detachment, vitreomacular traction, epiretinal membrane, vitreous hemorrhage or fibrosis involving the macula, ocular inflammation (uveitis), other retinal inflammatory or infectious diseases., Active or suspected periocular or ocular infection in the study eye. Mild noninfectious blepharitis is accepted., History of noninfectious uveitis in the study eye., Uncontrolled ocular hypertension or glaucoma in either eye, defined as IOP >22 mmHg while on more than 1 IOP-lowering medication at screening (Visit 1)., Subjects who plan to continue using contact lenses (including cosmetic contact lenses) during the study in the study eye., Subjects with high-risk proliferative diabetic retinopathy (PDR) as per CRC assessment at screening (Visit 1) only.

研究者

发起方

Oculis Operations S.a.r.l.

相似试验

尚未招募

3 期

Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema. (DIAMOND-2)

CTRI/2024/07/071429Oculis Operations Sàrl

进行中（未招募）

1 期

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)eovascular Age-Related Macular DegenerationMedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disorders

EUCTR2019-003923-39-CZBioeq GmbH434

已完成

3 期

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea in Patients with Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)eovascular Age-Related Macular Degeneration

JPRN-jRCT2080225278bioeq GmbH400

进行中（未招募）

1 期

EUCTR2019-003923-39-HUBioeq GmbH400

进行中（未招募）

1 期

Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age-Related Macular Degeneration (MAGELLAN-AMD)

EUCTR2019-003923-39-ITBIOEQ GMBH400